Among the earnings stories for Wednesday, Nov. 11, from AP Financial News:

Dendreon Corp., which is developing the prostate cancer drug Provenge, said Wednesday its third-quarter loss widened on a boost in operating expenses and costs to cover the value of warrants to buy its shares.

No doubt the widespread use of solar and wind power is ideal, but it’ll be a long time before the mass adoption of those alternative energies is a reality. In the meantime, Cramer says, the US should shift its focus to natural gas.

Dendreon has completed its U.S. regulatory submission for its closely watched experimental prostate cancer vaccine, the company said Monday, sending its shares up 5 percent.